论文部分内容阅读
目的:研究替吉奥联合顺铂治疗晚期胃癌的疗效和安全性。方法:42例晚期胃腺癌患者随机分为观察组(21例)与对照组(21例)两组,观察组采用替吉奥联合顺铂,对照组采用卡培他滨联合顺铂。结果:两组患者疗效间差异无统计学意义(P>0.05)。两组的不良反应主要为骨髓抑制、消化道反应和乏力,观察组Ⅲ～Ⅳ度血小板减少发生率显著低于对照组(P<0.05),Ⅲ～Ⅳ度手足综合征的发生率亦显著低于对照组(P<0.05)。结论:替吉奥联合顺铂治疗晚期胃癌疗效与卡培他滨联合顺铂相当,但其患者耐受性更好,值得临床进一步研究推广使用。
Objective: To study the efficacy and safety of tioguanide and cisplatin in the treatment of advanced gastric cancer. Methods: Forty-two patients with advanced gastric adenocarcinoma were randomly divided into two groups: observation group (21 cases) and control group (21 cases). The observation group was treated with tiotropium combined with cisplatin. The control group was treated with capecitabine combined with cisplatin. Results: There was no significant difference between the two groups (P> 0.05). Adverse reactions of the two groups were mainly myelosuppression, digestive tract reaction and fatigue. The incidence of Ⅲ ~ Ⅳ thrombocytopenia in the observation group was significantly lower than that in the control group (P <0.05), and the incidence of Ⅲ ~ Ⅳ hand-foot syndrome was also significantly lower In the control group (P <0.05). CONCLUSION: The efficacy of ticlopidine combined with cisplatin in the treatment of advanced gastric cancer is comparable to that of capecitabine combined with cisplatin, but its tolerability is better. It is worth further research to promote its use.